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Abstract
Background: The incidence of Japanese encephalitis (JE) has been dramatically reduced in China after sufficient
vaccine coverage. The live-attenuated Japanese encephalitis virus (JEV) vaccine SA14–14-2 is believed to have
strongly contribute to this decrease. Another vaccine that seems to have decreased in importance is an inactivated
vaccine based on the JEV P3 strain, which is considered to be modifiable, such as being transformed into a DNA
vaccine to improve its immunogenicity.
Methods: In this study, the protective efficacy induced by the Japanese encephalitis DNA vaccine candidate pV-
JP3ME encoding the premembrane (prM) and envelope (E) proteins of the P3 strain was assessed in BALB/c mice.
The prM/E genes of the JEV P3 strain were subcloned into the vector pVAX1 (pV) to construct pV-JP3ME.
Results: The plasmid DNA was immunized into BALB/c mice, and high titers of IgG antibody and neutralizing
antibody (nAb) against JEV were detected. The key cytokines in splenocytes were secreted upon stimulation with
JEV antigens. Finally, complete protective efficacy was generated after challenge with the JEV P3 strain in the mice.
Conclusions: The DNA vaccine pV-JP3ME based on the JEV P3 strain in this study can induce specific humoral
immune and cytokine responses and provide complete protection against JEV in mice.
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Background
Japanese encephalitis (JE) virus (JEV) is a single positive-
strand RNA virus belonging to the family Flaviviridae
genus Flavivirus [1]. JEV infection can cause severe
encephalitis, neurological sequelae, and even death in
children and adults [2]. JEV was first isolated in China in
1940 and is transmitted mainly by Culex mosquito bites,
with swine and wintering waterfowl as amplifying hosts
[3]. By the end of the 1980s, JEV infection had con-
stantly been a serious threat to the health of many Asian
children, and nearly half of all JE cases have occurred in
China. Since the development of two types of vaccina-
tions in China, an inactivated vaccine (strain P3) and the
live attenuated vaccine strain SA14–14-2 [4, 5], the
incidence of JE has decreased from 20.92 cases/100,000
individuals in 1971 to 0.12 cases/100,000 individuals in
2011 [6, 7]. China is still using the two vaccines men-
tioned above, and live-attenuated vaccines were included
in the national Expanded Programme on Immunization
(EPI) at the end of 2007 [8]. Given the more convenient
schedule, reduced toxicity, and better immunogenicity of
live-attenuated vaccines, SA14–14-2 has now replaced
inactivated vaccines [9]. Populations in some Asian coun-
tries and regions, such as Japan, South Korea, Taiwan, and
certain populations, including immunocompromised
people and those concerned about live vaccination, are
still using inactivated vaccines [10]. The wild-type P3
strain has strong virulence and contains many key
epitopes of immunogenicity, which can be improved by
biological modification. In this study, by combining the
biological characteristics of the virus and the advantages
of the DNA vaccine, the prM/E genes of the P3 strain
were subcloned into the DNA vaccine vector pVAX1 (pV)
to obtain the JEV DNA vaccine pV-JP3ME. The compre-
hensive immune response and protection induced by this
vaccine were evaluated, and this study will provide im-
portant data for its further application.
Materials and methods
Virus, cells, plasmids, and animals
JEV (strain P3) was stored at − 80 °C. It was used as the
coating antigen and stimulus for in vitro experiments
and used for challenge experiments.
Vero cells were used for plasmid transfection and
plaque assays to detect viral titers, and the plaque reduc-
tion neutralization test (PRNT) was used to detect the
nAb titers. C6/36 cells are used for virus proliferation
assays.
The pV-JP3ME plasmid was constructed by introdu-
cing the BamHI enzyme digestion site, Kozak sequence
and signal sequence upstream of the prM/E sequence of
the P3 strain and introducing the XhoI digestion site
downstream into the eukaryotic expression vector pV.
Specific pathogen-free 6- to 8-week-old female BALB/c
mice were used for immunity, sera and splenocyte collec-
tion and challenge tests. The results presented are from a
single experiment or are from three independent
experiments.
Reagents and instruments
The restriction enzymes BamHI and XhoI, eukaryotic
expression vector pV, nuclear staining agent 4′,6-diamidino-
2-phenylindole (DAPI), and transfection reagent Lipofecta-
mine 3000 were purchased from Thermo Scientific (USA).
Minimal essential medium (MEM) and RPMI-1640 medium
were purchased from Gibco (USA). Methylcellulose was
purchased from Sigma (USA). Goat anti-mouse fluorescein
isothiocyanate (FITC)-IgG antibody was purchased from
Beijing TransGen Biotech (China). Goat anti-mouse horse-
radish peroxidase (HRP)-IgG antibody was purchased from
Abcam (USA). Tetramethylbenzidine (TMB) substrate color
solution was purchased from MabTech Company (USA).
The enzyme-linked immunospot (ELISPOT) kit, streptavi-
din and AEC color development kit were purchased from
BD Company (USA). The gene introduction instrument was
purchased from Shanghai Teresa Corporation (China). The
enzyme-linked immunosorbent assay (ELISA) plate reader
and cell culture incubator were purchased from Thermo
(USA). The ELISPOT plate reader was purchased from CTL
(USA).
Transfection and immunofluorescence experiments
pV-JP3ME or pV was transfected into Vero cells. After
5 h, the transfection plasmid/reagent mixture was dis-
carded and replaced with complete culture medium.
After 40 h, the medium was discarded, and the two
groups of cells were simultaneously fixed. Then, the cells
were incubated with JEV antiserum (1:1000) as the pri-
mary antibody and goat anti-mouse FITC-IgG as the
secondary antibody. Observation of specific green fluor-
escence under a fluorescence microscope indicates that
the plasmid was successfully transfected and expressed
in mammalian cells in vitro. Fluorescence microscope
imaging was performed at 200× magnification, and the
microscope was from Nikon, Japan.
Animal experiments
The mice were randomly divided into two groups. The
vaccine group was vaccinated with the DNA vaccine pV-
JP3ME, and the control group was vaccinated with the
empty vector plasmid pV. Immunization was performed
three times, and each immunization dose was 50 μg.
Intramuscular injection (i.m.) with electroporation (EP)
was used. One and 3 weeks after the last immunization,
the splenocytes and sera of the two groups of mice were
collected, respectively. The next day, mice in the vaccine
and the control group were challenged with JEV. The
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body weight changes and the survival rate were
measured daily after the challenge, and the observation
continued for 12 consecutive days. The animal experi-
ment schedule is shown in Fig. 1.
Plaque assay
Vero cells were cultured in 24-well plates, and the cell
density was more than 95% before virus infection. The
serially diluted virus was serially diluted 10-fold from the
original solution (1:1) for a total of seven dilutions,
namely, 1:1 to 1:106. Two hundred microliters of the
virus dilution was added to each well and incubated at
37 °C for 1 h. The plate was gently shaken once every 15
min. After the dilution was discarded, 5 mL of MEM
medium containing 1.2% methylcellulose was added to
each well. After 4 d of culture, the medium was dis-
carded, and 1mL of crystal violet staining solution was
added to each well and stained for 30 min at room
temperature. The number of plaques per well was
counted, and the virus titer was calculated. The titer of
the virus solution was repeatedly measured three times,
and an average value was taken and is expressed as the
plaque-forming unit (PFU)/mL.
ELISA
Heat-inactivated JEV was coated in a 96-well plate at 105
PFU per well at 4 °C overnight. The coating antigen was
discarded and blocked with 1% bovine serum albumin
(BSA) at 37 °C for 2 h. The blocking solution was dis-
carded. The sera of each group of mice were started
from 1:100 and were serially diluted at a twofold ratio
for a total of 12 dilutions, namely, from 1:100 to 1:204,
800, and added to the wells in turn as a primary
antibody at 4 °C overnight. The next day, the primary
antibody was discarded. After the plate was washed five
times, HRP-labeled goat anti-mouse IgG antibody (1:
4000) was added as a secondary antibody. After incuba-
tion at 37 °C for 1 h, the plate was discarded. The sub-
strate solution developed color for 20 min, and the
reaction was stopped with H2SO4. We used 1/2 of the
A450 nm value at the 1:100 dilution of the control group
as the cut-off value, and the maximum dilution greater
than this cut-off value is the serum IgG antibody titer.
PRNT
Vero cells were cultured in 24-well plates as described
previously. The serum was diluted from 1:10 and serially
diluted at a 2-fold ratio. There are seven consecutive di-
lutions, that is, 1:10 to 1:640. Each dilution of serum was
mixed with an equal volume of virus solution (contain-
ing 100 PFU). For incubation at 37 °C for 1 h, serum-free
virus samples were set at 4 °C and 37 °C to exclude
temperature factors and reference positive virus counts.
Then, the serum/virus mixture was added to the wells in
order and incubated at 37 °C for 1 h. During the period,
the plate was shaken gently every 15 min. The subse-
quent step was the same as described in 2.5. The serum
dilution corresponding to a 50% reduction in the num-
ber of plaques in the positive wells incubated at 37 °C
was recorded as the PRNT50 value, which is the nAb
titer.
ELISPOT assay
IL-2 and IFN-γ capture antibodies diluted 1:200 were
coated in a 96-well plate at 4 °C overnight. We discarded
the coating solution and blocked with RPMI-1640
medium containing 10% FBS at room temperature for 2
h. Then, the splenocytes from the two groups were
added to each well at 2 × 105 cells per well, and 105 PFU
heat-inactivated JEV was added as a stimulus and cul-
tured at 37 °C for 72 h. After the cultured splenocytes
were discarded, IL-2 and IFN-γ detection antibodies
were added, and then, the spot forming units (SFUs)
were determined by adding streptavidin and AEC
chromogenic solution.
Statistical analysis
All experimental data were recorded using Excel 2016
software, statistical analysis was performed using SPSS
17.0 software (USA), the body weight change was
analyzed by repeated analysis of multivariate analysis of
variance, survival rates were compared using the log-
Fig. 1 Mouse experimental workflow. Groups of mice were immunized by intramuscular electroporation with 50 μg of either the pV-JP3ME DNA
vaccine or pV in each limb individually and were boosted twice at three-week intervals. Splenocytes were obtained 1 week after the final
immunization, and sera were collected 3 weeks after the final immunization. Subsequently, the vaccinated mice were challenged with 1 × 105
PFU of the JEV P3 strain. The body weight changes and the survival rates were observed for 12 consecutive days after the challenge
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rank test, and the differences between the groups were
compared using one-way ANOVA. Quantitative data are
expressed as the mean ± standard deviation. P < 0.05 was
considered statistically significant.
Results
The target protein prM/E was successfully expressed in
eukaryotic cells
As shown in Fig. 2, after Vero cells were transfected with
pV-JP3ME, the expressed target protein could bind to the
JEV antisera and showed specific green fluorescence, while
the Vero cells transfected with the empty vector plasmid
pV showed no specific fluorescence. These results indi-
cated that the target protein prM/E can successfully be
expressed in eukaryotic cells and has reactogenicity, which
can be used for subsequent experimental research.
Vaccination of mice with pV-JP3ME induces high levels of
JEV-specific IgG antibodies in immune sera
As shown in Fig. 3a, 3 weeks after the last immunization,
the sera of the vaccine group and the control group were
collected, and the titer of the anti-JEV-specific IgG anti-
bodies was measured by ELISAs. Higher IgG antibodies
against JEV were detected in the sera of mice in the
vaccine group than in the control group, with a titer of 1:
4200 compared with 1:163 in the control group (P <
0.001). There is a significant difference between the
groups, as shown in Fig. 3a, indicating that after
immunization with the JEV DNA vaccine pV-JP3ME,
mice can induce high levels of IgG antibodies against JEV.
Robust neutralizing activity was found in the immune sera
The titer of anti-JEV-specific nAb was measured by
PRNT. The results showed that the nAb titer against
JEV in the sera of the vaccine group was 1:380 and that
in the control group was 1:11 (P < 0.001). There was a
significant difference between the groups, as shown in
Fig. 3b, suggesting that after pV-JP3ME immunization,
mouse sera had neutralizing activity against JEV.
Inflammatory cytokines were produced upon stimulation
with the JEV antigen
One week after the last immunization, splenocytes of the
vaccine group and the control group were obtained, and
ELISPOT was used to determine the number of IL-2-
and IFN-γ-spots forming cells per 105 splenocytes upon
stimulation with the JEV antigen. The results showed
that the spots of IL-2 and IFN-γ were significantly
greater in the splenocytes of the vaccine group than in
those of the control group in vitro (P < 0.01), as shown
in Fig. 3c and d. After the mice were immunized with
pV-JP3ME, the splenocytes secreted higher levels of IL-2
and IFN-γ after stimulation with the JEV antigen, sug-
gesting a better antiviral cytokine response.
Vaccinated mice were fully resistant to lethal doses of JEV
To evaluate the protective efficacy of the JEV DNA vac-
cine pV-JP3ME in mice, we used 1 × 105 PFU of JEV to
intraperitoneally (i.p.) challenge the mice in the vaccine
and the control group, and the changes in body weight
and the survival rate were recorded and compared for 12
consecutive days. After the challenge with JEV, the body
weight change of the vaccinated mice showed a steady
trend during the observation period, and the differences
between individuals were limited, while the body weight
of the control mice continued to decline. A significant
difference was shown between the two groups (P < 0.01,
Fig. 4a). In terms of the survival rate, the mice in the
vaccine group were fully protected, with a survival rate
of 100% (8/8), while the mice in the control group began
to die on the sixth day, and all died on the twelfth day
Fig. 2 Representative images of immunofluorescence after Vero cells were transfected with plasmid DNA. After Vero cells were transfected with
pV-JP3ME or pV, JEV antiserum was used as the primary antibody, and goat anti-mouse FITC-IgG was used as the secondary antibody for staining.
The left image a shows specific green fluorescence, but the right image b does not (× 200)
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(0/8). The difference between the groups was statistically
significant (P < 0.001, Fig. 4b).
Discussion
Currently, the JEV vaccine widely used in China is the
live attenuated vaccine strain SA14–14-2. This vaccine
has a good efficacy and, in addition to China, many
Asian countries have approved it for use. Furthermore,
another self-developed inactivated vaccine, the P3 strain,
is still in use in China. The P3 strain used for special
populations (based on concerns about live vaccines or
unsafe vaccine incidents in society). However, the P3
Fig. 4 Protective effect generated by mice after immunization. In the third week after the mice were immunized with 3 pV-JP3ME or pV doses,
the challenge test was performed. The mice in the vaccine group had no significant body weight changes within 12 days, while the control
group showed a continual decline. Similarly, the mice in the vaccine group were completely protected, and the survival rate was up to 100%,
while the mice in the control group all died. **P < 0.01, ***P < 0.001, n = 8 per group
Fig. 3 Specific humoral immune response and cytokine secretion produced by mice after immunization. In the third week after the mice were
immunized three times with pV-JP3ME or pV, a IgG antibodies and b nAbs were produced with higher titers in the vaccine group than in the
control group. One week after immunization, the mouse splenocytes produced high levels of c IL-2 and d IFN-γ upon JEV antigen stimulation.
**P < 0.01, ***P < 0.001, n = 8 per group
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inactivated vaccine rather than the SA14–14-2 vaccine is
not included in the EPI; the former requires full pay-
ment by the patient, but it still has a solid market share
as described above. In some Asian countries and regions,
such as South Korea, Japan, and Taiwan, inactivated vac-
cines are customary and considered safe. Most of the
inactivated vaccines used are the Nakayama strain [11],
which originated from Japan and still predominates in
the JEV vaccine market, although different types of live
attenuated vaccines have been introduced into these re-
gions. Inactivated vaccines do have some disadvantages
that cannot be compared with live-attenuated vaccines,
such as low immunogenicity, a significant Th2-type im-
mune trend, and a requirement for multiple immunizations
[12]. However, in terms of its safety, inactivated vaccines do
not show virulence recovery and reproducibility, which still
makes them highly desired in many JE-affected countries.
The vaccinated population is mainly children around the
age of 1 year, and safety cannot be ignored.
The SA14–14-2 live-attenuated vaccine requires only
two injections, while the inactivated P3 vaccine re-
quires four or more vaccinations to achieve sufficient
protection. This phenomenon strongly limits the
vaccine as the first choice for emergency vaccines for
travelers. Even in JE-endemic countries such as China,
this vaccine is not optimal in comparisons. It is diffi-
cult to develop a live attenuated vaccine based on the
P3 strain, and even if it is successful, it is difficult to
compete with the existing SA14–14-2 strain because
the latter has been certified and recommended by the
World Health Organization. In comparison, DNA
vaccines have been used in vaccine design in recent
years to prevent and treat multiple pathogens and
diseases, such as infectious diseases including dengue
virus, human immunodeficiency virus, and malaria and
tumors [13, 14]. DNA vaccines have been approved for
veterinary use, but there are no approved vaccines for
human use [15]. Due to the balanced immune response
and the long-lasting effect induced by DNA vaccines,
they have become a popular alternative.
Therefore, in this study, the most antigenic structural
protein, prM/E, of the JEV strain P3 was used as a target
to construct a DNA vaccine. First, we verified the suc-
cess or failure of expressing the target antigen in the
transfection experiments of mammalian cells in vitro.
The vaccine expresses the target protein, which can sta-
bly bind to JEV-specific antibodies, suggesting that it has
good reactivity. Regarding the route, time and dose of
immunizations, we have already fully studied other flavi-
virus vaccines, such as dengue virus and Zika virus, and
will not discuss them here.
After three immunizations with the vaccine, mice show
high titer IgG antibodies and nAb in vivo. Furthermore,
the splenocytes of the immunized mice produced high
levels of the cytokines IL-2 and IFN-γ upon stimulation
with JEV-specific antigens. IL-2 plays an important role in
the maturation, proliferation, and activation of T cells.
IFN-γ is one of the most important innate and acquired
antiviral cytokines and can play an antiviral role in both
innate and adaptive immunity [16]. We selected these two
representative cytokines for testing, suggesting that the
vaccine is immunogenic. Furthermore, in the challenge
test in vivo, pV-JP3ME provided complete protection for
the mice, resulting in resistance to the lethal dose of JEV,
while the mice in the control group all died. The above
results indicate that the prM/E protein of the P3 strain is
sufficient as a target protein candidate of the JEV vaccine
to induce effective immunoprotection [17].
In recent years, there have been many studies on SA14–
14-2, and the results showed the scalability of the vaccine.
Erra et al. prepared an inactivated vaccine by using the live
attenuated vaccine SA14–14-2 strain [18], and Appaiahgari
et al. replaced the prM/E of the yellow fever virus attenu-
ated strain 17D with that of SA14–14-2 by using chimeric
recombination [19]; they also obtained a good immune ef-
fect. One of the reasons for selecting the P3 strain in this
study is that the virulence of the P3 strain is closer to that
of the wild type strain than SA14–14-2, and it is presented
in the form of a DNA vaccine to ensure that there is no
possibility of virulence recovery. The expressed target pro-
tein is similar to the natural conformation of the original
strain prM/E protein containing key epitopes that are not
displayed in the attenuated strain. Second, P3 is an inacti-
vated vaccine strain widely used in China, and recombinant
construction can be used in combination with the P3 inac-
tivated vaccine in heterogeneous immunization in subse-
quent studies. Previous studies have reported that a DNA
vaccine constructed using a specific target protein can be
used as the prime immunization, a protein component vac-
cine (subunit vaccine) is prepared with the same target pro-
tein is boosted, and the immune response is more robust
than that of homologous immunization, namely, DNA
alone or subunit immunization alone [20]. The level of the
immune response induced by heterologous immunization
is higher and more balanced than single immunization, and
the protective effect is also improved. This strategy is ex-
pected to reduce the times of immunization compared with
immunization with an inactivated vaccine alone, and theor-
etically, it can also improve the immunogenicity and long-
term immune response induced by the vaccine [21, 22],
which warrants further experiments.
Conclusions
In summary, this study used the P3 strain to construct a
JEV DNA vaccine candidate, evaluated its immunogenicity
and protective effect in mice, and confirmed that the
vaccine can induce JEV-specific humoral and cytokine
responses and provide complete protection against JEV in
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mice. Our data will provide a basis for the subsequent
promotion and use of the vaccine and lay the foundation
for its combined use with inactivated vaccines of the same
strain in a heterologous regimen.
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